NeuroOne Medical Technologies Co. (NASDAQ:NMTC) Sees Large Drop in Short Interest

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 70,300 shares, a decrease of 37.1% from the December 15th total of 111,800 shares. Based on an average daily volume of 173,400 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Investors Weigh In On NeuroOne Medical Technologies

An institutional investor recently raised its position in NeuroOne Medical Technologies stock. Geode Capital Management LLC raised its stake in NeuroOne Medical Technologies Co. (NASDAQ:NMTC) by 9.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 283,855 shares of the company’s stock after purchasing an additional 24,972 shares during the quarter. Geode Capital Management LLC owned 0.92% of NeuroOne Medical Technologies worth $281,000 at the end of the most recent reporting period. 16.07% of the stock is currently owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Stock Down 1.0 %

NASDAQ:NMTC opened at $1.12 on Tuesday. The company has a market capitalization of $34.54 million, a PE ratio of -2.33 and a beta of 0.41. NeuroOne Medical Technologies has a 52-week low of $0.55 and a 52-week high of $1.59. The stock’s 50 day moving average price is $0.80 and its 200 day moving average price is $0.84.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings results on Tuesday, December 17th. The company reported ($0.11) EPS for the quarter. NeuroOne Medical Technologies had a negative net margin of 308.51% and a negative return on equity of 276.12%.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.